AUPM672594A0 - A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders - Google Patents

A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders

Info

Publication number
AUPM672594A0
AUPM672594A0 AUPM6725A AUPM672594A AUPM672594A0 AU PM672594 A0 AUPM672594 A0 AU PM672594A0 AU PM6725 A AUPM6725 A AU PM6725A AU PM672594 A AUPM672594 A AU PM672594A AU PM672594 A0 AUPM672594 A0 AU PM672594A0
Authority
AU
Australia
Prior art keywords
prophylaxis
proliferative
treatment
skin disorders
inflammatory skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPM6725A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Childrens Hospital Research Foundation
Original Assignee
Royal Childrens Hospital Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Childrens Hospital Research Foundation filed Critical Royal Childrens Hospital Research Foundation
Priority to AUPM6725A priority Critical patent/AUPM672594A0/en
Publication of AUPM672594A0 publication Critical patent/AUPM672594A0/en
Priority to NZ289028A priority patent/NZ289028A/xx
Priority to PCT/AU1995/000410 priority patent/WO1996001636A1/fr
Priority to AU28753/95A priority patent/AU692278B2/en
Priority to JP8504013A priority patent/JPH10508286A/ja
Priority to NZ329202A priority patent/NZ329202A/xx
Priority to CA002194366A priority patent/CA2194366A1/fr
Priority to US08/666,392 priority patent/US5929040A/en
Priority to EP95924110A priority patent/EP0776210A4/fr
Priority to US09/199,926 priority patent/US6284741B1/en
Priority to US09/791,196 priority patent/US20030096769A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
AUPM6725A 1994-07-08 1994-07-08 A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders Abandoned AUPM672594A0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AUPM6725A AUPM672594A0 (en) 1994-07-08 1994-07-08 A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
EP95924110A EP0776210A4 (fr) 1994-07-08 1995-07-06 Methode destinee a la prophylaxie et/ou au traitement d'affections proliferatives et/ou inflammatoires de la peau
JP8504013A JPH10508286A (ja) 1994-07-08 1995-07-06 増殖性及び／又は炎症性皮膚障害の予防法及び／又は治療法
PCT/AU1995/000410 WO1996001636A1 (fr) 1994-07-08 1995-07-06 Methode destinee a la prophylaxie et/ou au traitement d'affections proliferatives et/ou inflammatoires de la peau
AU28753/95A AU692278B2 (en) 1994-07-08 1995-07-06 A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
NZ289028A NZ289028A (en) 1994-07-08 1995-07-06 Use of antisense nucleic acids in the treatment of skin disease
NZ329202A NZ329202A (en) 1994-07-08 1995-07-06 Treatments for ameliorating the effects of psoriasis using compounds that inhibit cell proliferative and/or inflammation
CA002194366A CA2194366A1 (fr) 1994-07-08 1995-07-06 Methode destinee a la prophylaxie et/ou au traitement d'affections proliferatives et/ou inflammatoires de la peau
US08/666,392 US5929040A (en) 1994-07-08 1995-07-06 Method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US09/199,926 US6284741B1 (en) 1994-07-08 1998-11-25 Method for the prophylaxis and/or treatment of proliferative and /or inflammatory skin disorders
US09/791,196 US20030096769A1 (en) 1994-07-08 2001-02-23 Method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM6725A AUPM672594A0 (en) 1994-07-08 1994-07-08 A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders

Publications (1)

Publication Number Publication Date
AUPM672594A0 true AUPM672594A0 (en) 1994-08-04

Family

ID=3781291

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPM6725A Abandoned AUPM672594A0 (en) 1994-07-08 1994-07-08 A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders

Country Status (7)

Country Link
US (3) US5929040A (fr)
EP (1) EP0776210A4 (fr)
JP (1) JPH10508286A (fr)
AU (1) AUPM672594A0 (fr)
CA (1) CA2194366A1 (fr)
NZ (2) NZ289028A (fr)
WO (1) WO1996001636A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US6147056A (en) * 1995-06-06 2000-11-14 Trustees Of Boston University Use of locally applied DNA fragments
US6518017B1 (en) * 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US20030165888A1 (en) 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
US6020339A (en) * 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
JP4785252B2 (ja) 1999-02-26 2011-10-05 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｔｒｐｍ−２アンチセンス療法
DE60023480T2 (de) * 1999-04-08 2006-07-20 Gen-Probe Inc., San Diego Amplifikation und sequenzierung von primer-paaren und deren verwendung
CA2365984A1 (fr) * 1999-04-08 2000-10-19 Oasis Biosciences, Inc. Oligonucleotides anti-sens contenant des bases universelles et/ou degenerees
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
KR20070118315A (ko) * 1999-04-21 2007-12-14 와이어쓰 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
US6900186B1 (en) * 1999-06-21 2005-05-31 Murdock Children's Research Institute Method for the prophylaxis and/or treatment of medical disorders
EP1191941A4 (fr) * 1999-06-21 2006-12-13 Murdoch Childrens Res Inst Methode de prophylaxie et/ou de traitement de troubles cliniques
US6770633B1 (en) 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
CA2388924A1 (fr) * 1999-10-26 2001-05-03 Joan M. Robbins Therapie ribozymique destinee au traitement de maladies proliferantes de la peau et des yeux
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1317470B1 (fr) * 2000-09-14 2011-04-27 The University Of British Columbia Oligodesoxynucleotides antisens, proteines de fixation du facteur de croissance insulinoide 2 (igfbp-2) pour le traitement du cancer de la prostate
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
US6861406B2 (en) * 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
WO2003062421A1 (fr) * 2002-01-17 2003-07-31 The University Of British Columbia Oligonucleotides antisens bispecifiques qui inhibent l'igfbp-2 et l'igfbp-5 et procedes d'utilisation associes
DE10233994A1 (de) * 2002-07-25 2004-02-12 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Nukleinsäuren auf der Basis nicht-methylierter CpG-Motive
SI1530636T1 (sl) * 2002-08-21 2010-12-31 Stry Liaison Ofiice The University Of British Columbia Umiversity Indu Zdravljenje melanoma z zniĹľanjem nivojev klusterina
AU2007216630B2 (en) * 2002-08-21 2010-09-16 The University Of British Columbia RNAi probes targeting cancer-related proteins
KR101238701B1 (ko) * 2002-08-21 2013-03-05 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US20060276394A1 (en) * 2002-11-14 2006-12-07 Wyeth Methods and compositions for treating neurological disorders
CA2504607A1 (fr) * 2002-11-14 2004-05-27 Wyeth Methodes et compositions permettant de traiter des troubles neurologiques
AU2003900481A0 (en) 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US7846906B2 (en) * 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040224914A1 (en) * 2003-04-18 2004-11-11 The University Of British Columbia Method for treatment of angiogenic disorders
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
EP1667731B1 (fr) * 2003-10-01 2013-05-22 The University Of British Columbia Oligonucleotide bispecifique pour le traitement des malignites du systeme nerveux central
DE10361502A1 (de) * 2003-12-23 2005-07-28 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Superstruktur-bildende Nukleinsäure-Sequenzen
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
CA2584646C (fr) * 2004-11-23 2015-11-03 The University Of British Columbia Traitement du cancer avec combinaison d'un agent qui perturbe la voie de signalisation egf et d'un oligonucleotide qui reduit les niveaux de clusterine
PT1828249E (pt) 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
NZ564098A (en) 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
US8383598B2 (en) * 2005-10-12 2013-02-26 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
CN102725308A (zh) 2009-11-30 2012-10-10 昆士兰技术大学 纤连蛋白:生长因子嵌合物
EP2563922A1 (fr) * 2010-04-26 2013-03-06 Marina Biotech, Inc. Composés d'acide nucléique ayant des monomères à conformation restreinte et leurs utilisations
CA2866819C (fr) 2012-03-13 2022-01-04 James Cook University Procede de traitement de l'inflammation
JP2016532456A (ja) 2013-09-18 2016-10-20 ジェームス・クック・ユニバーシティー 改変型抗炎症性タンパク質及び使用方法
WO2018077889A1 (fr) * 2016-10-24 2018-05-03 Almirall, S.A. Compositions comprenant du linsitinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
JPH08508405A (ja) * 1993-03-26 1996-09-10 トーマス ジェファーソン ユニバーシティ Ｉｇｆ−１レセプターアンチセンスオリゴヌクレオチドにより細胞の増殖を阻害し、且つ細胞を分化させる方法
WO1994023034A2 (fr) * 1993-04-06 1994-10-13 Cedars-Sinai Medical Center Sous-unites de recepteurs du facteur de croissance i semblables a l'insuline, et procedes d'utilisation
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
WO1996010401A1 (fr) * 1994-10-04 1996-04-11 Emory University Procedes de regulation du recepteur du facteur de croissance de type 1 proche de l'insuline

Also Published As

Publication number Publication date
WO1996001636A1 (fr) 1996-01-25
US5929040A (en) 1999-07-27
EP0776210A1 (fr) 1997-06-04
CA2194366A1 (fr) 1996-01-25
NZ329202A (en) 2001-08-31
US6284741B1 (en) 2001-09-04
JPH10508286A (ja) 1998-08-18
NZ289028A (en) 1998-01-26
EP0776210A4 (fr) 2000-06-07
US20030096769A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
AUPM672594A0 (en) A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
AU3371493A (en) Method for improving the quality of sleep and treating sleep disorders
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
AU3548795A (en) Benzopyranopyrazolyl derivatives for the treatment of inflammation
AU4880197A (en) Method for treatment of dermatological disorders
AU2277595A (en) Device and method for treatment of skin
AU7516994A (en) Method and device for treating bone disorders
AU3738293A (en) Compounds useful for treating allergic and inflammatory diseases
AU4995693A (en) Apparatus and method for the treatment of blood
EP0717592A4 (fr) Procede et composition de traitement du syndrome d'apathie-amotivation
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
AU2804297A (en) Method of and composition for treating disorders of the skin using vitamin k
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU1438295A (en) Method for treatment of papulo-pustules and comedones of the skin
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AUPM771894A0 (en) Method for the treatment of indirect inguinal hernias and related conditions
AU2843397A (en) Agent for prophylaxis and treatment of disturbance of visual function
AUPN104895A0 (en) Methods of and preparations for the treatment of ailments and disorders
AU3861595A (en) A screw and method for the manufacturing and treatment of a screw
AU2548595A (en) Auto-tuning controller and method of use therefor
AU2875395A (en) A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
IL128095A0 (en) Formulation for the treatment and/or prophylaxis of dementia
AUPO439396A0 (en) A method of treatment and prophylaxis
AUPM836794A0 (en) Improved method and composition for the treatment of ulcers